FindTrial
Sign In

PD-1 Knockout T Cells

BIOLOGICAL6 trials

Sponsors

Sichuan University, Peking University, Hangzhou Cancer Hospital, The First Affiliated Hospital of Guangdong Pharmaceutical University

Conditions

Esophageal CancerHormone Refractory Prostate CancerInvasive Bladder Cancer Stage IVMetastatic Non-small Cell Lung CancerMetastatic Renal Cell CarcinomaProstate Cancer

Phase 1

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
CompletedNCT02793856
Sichuan UniversityMetastatic Non-small Cell Lung Cancer
Start: 2016-08-26End: 2020-03-17Updated: 2021-01-12
PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
WithdrawnNCT02863913
Peking UniversityInvasive Bladder Cancer Stage IV
Start: 2016-09-30End: 2019-09-30Updated: 2019-03-06
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
WithdrawnNCT02867332
Peking UniversityMetastatic Renal Cell Carcinoma
Start: 2016-11-30End: 2020-11-30Updated: 2019-03-06
Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment
NCT03525652
The First Affiliated Hospital of Guangdong Pharmaceutical UniversityProstate Cancer
Start: 2018-02-22End: 2021-08-30Target: 30Updated: 2018-05-16

Unknown Phase

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
WithdrawnNCT02867345
Peking UniversityHormone Refractory Prostate Cancer
Start: 2016-11-30End: 2020-12-31Updated: 2019-03-06
PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
CompletedNCT03081715
Hangzhou Cancer HospitalEsophageal Cancer
Start: 2017-03-14End: 2018-02-28Updated: 2019-06-12

Related Papers

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
2020-04-27387 citations
Abstract CT133: A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer with PD-L1 expression
Cancer Research2018-07-019 citations
A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer.
Journal of Clinical Oncology2018-05-2030 citations
Safety and activity of programmed cell death-1 gene knockout engineered t cells in patients with previously treated advanced esophageal squamous cell carcinoma: An open-label, single-arm phase I study.
Journal of Clinical Oncology2018-05-2026 citations